跳至主要内容
临床试验/NCT06418230
NCT06418230进行中(未招募)不适用

EXOME SEQUENCING IN MEDULLARY SPONGE KIDNEY

Hospices Civils de Lyon2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年1月2日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
80
试验地点
2
主要终点
Class 3, 4 and 5 variants detected at exome-sequencing

研究概览

简要总结

Medullary sponge kidney is a rare, underdiagnosed renal pathology, characterized by precalyceal dilatation of the renal tubes associated with active and recurrent stone disease with nephrocalcinosis, hypercalciuria and tubular dysfunction with, for example, acidification and urinary concentration defects.

The pathophysiology is poorly understood The prevalence and etiopathogenesis of the disease is not known Medullary sponge kidney is often characterized as a congenital pathology with delayed expression due to reported cases occurring in early childhood and associations with other congenital renal and extra-renal malformative pathologies, such as Wilms tumors, horseshoe kidney, contralateral renal hypoplasia, Beckwith-Wiedemann syndrome, Caroli disease, or congenital hepatic fibrosis, for example. However, no clear demonstration of the congenital nature has been established so far, and it is considered a sporadic disease.

However familial cases have been reported with an autosomal dominant mode.

The pathophysiology may involve disruptions in renal organogenesis, which depends on reciprocal inductive interactions necessary to coordinate nephrogenesis between the ureteric bud and the metanephric blastema during the 5th week of embryonic development. Some authors suggested that the GDNF and RET genes may be involved in the physiopathology of the disease.

For instance 12% of heterozygous patients for rare GDNF variants were identified in an Italian cohort of 57 medullary sponge kidney patients.

Other genes have been suggested to be involved in the pathophysiology based on reported cases, with no direct relationship demonstrated and their role remain putative Medullary sponge kidney disease is a debilitating condition, with the main symptoms being recurrent kidney stones and urinary infections.

Additional data are needed to determine the involvement of genetic anomalies in the pathophysiology of the condition.

The aim of the study is to describe the genetic variants identified with exome sequencing in medullary sponge kidney patients, in order to optimize management, especially for familial forms, and therapeutic interventions.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • medullary sponge kidney attending medical consultation
  • consent signed
  • affiliated to social insurance scheme

排除标准

  • legal protection measure (guardianship, curatorship)
  • Deprived of liberty by a judicial or administrative decision
  • subject participating in another research including an exclusion period still in progress at inclusion

结局指标

主要结局

Class 3, 4 and 5 variants detected at exome-sequencing

时间窗: Baseline

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
不适用
Multiparametric Magnetic Resonance Imaging (MRI) in Medullary Sponge KidneyMedullary Sponge Kidney
NCT05682053Hospices Civils de Lyon33
进行中(未招募)
不适用
Studying the onset of Diabetes Mellitus in patients with a kidney tranplant getting anti-rejection therapy with Advagraf when used with or without steroids.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 14.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2010-019638-28-HUAstellas Pharma Europe Ltd.1,166
进行中(未招募)
不适用
Studying the onset of Diabetes Mellitus in patients with a kidney tranplant getting anti-rejection therapy with Advagraf when used with or without steroids.
EUCTR2010-019638-28-EEAstellas Pharma Europe Ltd.1,166
进行中(未招募)
不适用
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY - ADVANCERenal transplantationMedDRA version: 9.1Level: LLTClassification code 10023438
EUCTR2010-019638-28-ITASTELLAS PHARMA1,166
进行中(未招募)
不适用
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY - ADVANCEProphylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 12.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejection
EUCTR2010-019638-28-NLAstellas Pharma Europe Ltd.1,166
EXOME SEQUENCING IN MEDULLARY SPONGE KIDNEY | 临床试验